Fractyl Labs today announced the closing of a $100 million Series F financing round in addition to a name change to Fractyl Health. Lexington, Mass.-based Fractyl Health received contributions to the round from new investors Maverick Capital, M28 … [Read More...] about Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Smiths Medical recalls some insulin syringes over skewed graduation marking
Smiths Medical announced today that it issued recall notices for its Jelco Hypodermic Needle-Pro fixed needle insulin syringes. Minneapolis-based Smiths Medical became aware of specific models and lots of the Jelco Hypodermic Needle-Pro fixed … [Read More...] about Smiths Medical recalls some insulin syringes over skewed graduation marking
Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health
Fractyl Labs today announced the closing of a $100 million Series F financing round in addition to a name change to Fractyl Health. Lexington, Mass.-based Fractyl Health received contributions to the round from new investors Maverick Capital, M28 … [Read More...] about Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health
Diabetes Center Berne launches open innovation challenge for diabetes tech
The Diabetes Center Berne today announced the launch of an initiative to develop technology to address the treatment of diabetes. DCB is seeking innovators, co-creators, scientists and members of the diabetes community to join the company's … [Read More...] about Diabetes Center Berne launches open innovation challenge for diabetes tech
MedinCell to begin regulatory development of long-acting injectable malaria treatment
MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development. Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month … [Read More...] about MedinCell to begin regulatory development of long-acting injectable malaria treatment
FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Incyte (NSDQ:INCY) announced today that the FDA extended the review period for the new drug application for its ruxolitinib cream. Wilmington, Del.-based Incyte designed its ruxolitinib cream to treat atopic dermatitis (AD). The company designed … [Read More...] about FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Cardinal Health wins new FDA approval for Lymphoseek
Cardinal Health (NYSE:CAH) announced today that the FDA approved its Lymphoseek injection for pediatric use. Dublin, Ohio-based Cardinal Health touts Lymphoseek — acquired from Navidea Biopharmaceuticals (NYSE:NAVB) in November 2016 — as the first … [Read More...] about Cardinal Health wins new FDA approval for Lymphoseek
Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos' iDose TR implant contains a novel formulation of travoprost, … [Read More...] about Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its … [Read More...] about ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
Ananda Scientific enrolls first patient in Liquid Structure CBD trial for treating PTSD
Ananda Scientific announced today that it enrolled the first patient in a trial evaluating its Liquid Structure delivery system for treating PTSD. In collaboration with the NYU Grossman School of Medicine, Ananda's clinical trial will evaluate … [Read More...] about Ananda Scientific enrolls first patient in Liquid Structure CBD trial for treating PTSD
BD surpasses 2 billion orders for COVID-19 vaccine injection devices
BD (NYSE:BDX) announced today that orders for its needles and syringes hit 2 billion amid global COVID-19 vaccination efforts. Franklin Lakes, N.J.-based BD's latest milestone comes less than six months after the company surpassed 1 million orders … [Read More...] about BD surpasses 2 billion orders for COVID-19 vaccine injection devices
In case you missed it
- Tandem Diabetes Care touts study results for insulin pump with closed-loop technology
- Carbon Health acquires Steady Health and its diabetes platform
- Dexcom touts CGM studies, shares data on next-gen G7
- Study shows CGMs better at controlling blood sugar in type 2 diabetes
- Medtronic touts real-world results for MiniMed 780G insulin pump
- FDA accepts resubmitted NDA for Xipere from Clearside Biomedical, Bausch Health
- Lyra inks $135M partnership to expand chronic rhinosinusitis treatment in Asia
- SEC lawsuit accuses RenovaCare of securities fraud
- Noveome Biotherapeutics inks licensing deal for SipNose drug delivery device
- NRx Pharmaceuticals touts Zyesami results, seeks EUA for treating COVID-19
- DarioHealth touts research on digital therapeutics for diabetes patients
- Phillips-Medisize unveils Aria smart autoinjector
- Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor
- Retractable Technologies wins $27M federal contract
- Nanoform, Celanese partner to develop nanoparticle-enabled drug delivery
Clinical Trials
Fractyl raises $100M for diabetes reversal tech, renamed as Fractyl Health
Fractyl Labs today announced the closing of a $100 million Series F financing round in addition to a name change to Fractyl Health. Lexington, Mass.-based Fractyl Health received contributions to the round from new investors Maverick Capital, M28 Capital and Population Health Partners, while other new and existing investors participated, too. According to a news […]
MedinCell to begin regulatory development of long-acting injectable malaria treatment
MedinCell announced that its long-acting injectable malaria treatment is ready to enter into the stages of regulatory development. Montpellier, France–based MedinCell conducted an in vivo proof of concept on cattle that demonstrated three-month mosquitocidal effectiveness in the injectable, long-acting formulation of Ivermectin using the company’s BEPO delivery technology. The company designed the investigational mdc-STM product […]
FDA extends NDA review period for Incyte’s atopic dermatitis therapeutic cream
Incyte (NSDQ:INCY) announced today that the FDA extended the review period for the new drug application for its ruxolitinib cream. Wilmington, Del.-based Incyte designed its ruxolitinib cream to treat atopic dermatitis (AD). The company designed the proprietary formulation of its selective JAK1/JAK2 inhibitor ruxolitinib for topical application, according to a news release. Currently, the ruxolitinib […]
Glaukos completes enrollment in Phase 3 trials for iDose TR drug-eluting implant
Glaukos (NYSE:GKOS) announced today that it completed enrollment for a Phase 3 clinical program for its iDose TR sustained-release travoprost implant. San Clemente, Calif.–based Glaukos’ iDose TR implant contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP) through a design that continuously releases therapeutic levels of the medication for […]
ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies
ViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million. San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients […]
